DCG-IV is a potent group II metabotropic glutamate receptor (mGluR2/3) agonist with EC50 values of 0.35 μM and 0.09 μM for mGluR2 and mGluR3, respectively; it also acts as a competitive antagonist at group I (mGluR1/5, IC50 = 389/630 μM) and group III (mGluR4/6/7/8, IC50 = 22.5/39.6/40.1/32 μM) receptors; exhibits anticonvulsant and neuroprotective effects; functions as an NMDA receptor agonist in rat cortical slices; and suppresses phencyclidine (PCP)-induced hyperlocomotion in mice at doses of 1–10 mg/kg (i.p.).